ClinicaliQ Trial Snapshot
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Active Not Recruiting • Phase III • NCT04181827.
- CAR-T cell therapy cilta-cel compared with standard chemotherapy in patients with relapsed multiple myeloma resistant to lenalidomide.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd). Conditions: Multiple Myeloma Interventions: Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 419 participants